Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: A novel, safe, and active regimen

Gastric Cancer

Volumn 9, Issue 2, 2006, Pages 99-105

  Murad, André M ^a   Skare, Nils G ^b   Vinholes, Jéferson ^c   Lago, Sérgio ^d   Pecego, Ricardo ^e  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Hospital Erasto Gaertner   (Brazil)

^c Unidade de Pesquisa   (Brazil)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

5 Fluorouracil; Docetaxel; Epirubicin; Gastric cancer

Indexed keywords

ANALGESIC AGENT; DOCETAXEL; EPIRUBICIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; MALE; MULTICENTER STUDY; MYALGIA; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 33745131433     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-006-0361-z     Document Type: Article

References (42)

1. D Ho 1988 Epidemiologic studies in gastric cancer D Ho Gastric cancer Churchill Livingstone New York, NY 1 25
2. Ministry of Health, Brazil. National Secretariat of Health Assistance. National Câncer Institute of Brazil. Cancer Control Program Coordination. - Pro-Onco. Estimates of Cancer: Incidence and Mortality in Brazil, 2002. Rio de Janeiro, Brasil. Available from: http://www.inca.gov.br/ (accessed May 14, 2004)
3. M Findlay D Cunningham 1993 Chemotherapy of carcinoma of the stomach Cancer Treat Rev 19 29 44
4. J Rubin JG Gallagher G Schroeder AJ Schutt RJ Dalton JW Kugler 1996 Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma Cancer 78 1888 91
5. C Louvet A De Gramont B Demuynck B Nordlinger JE Maisani B Lagadec 1991 High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer Ann Oncol 2 229 30
6. AM Murad 1999 Chemotherapy for advanced gastric cancer: focus on new agents and combinations Cancer Control 6 361 8
7. NK Kim YS Park DS Heo C Suh SY Kim KC Park 1993 A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813 18
8. J Wils HO Klein DJ Wagener H Bleiberg H Reis F Korsten 1991 Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer - a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group J Clin Oncol 9 827 31
9. G Cocconi M Bella S Zironi R Algeri F Di Costanzo V De Lisi 1994 Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research J Clin Oncol 12 2687 93
10. D Kelsen OT Atiq L Saltz D Niedzwiecki D Ginn D Chapman 1992 FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer J Clin Oncol 10 541 8
11. U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 57
12. A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe 1997 Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261 7
13. J Crown M O'Leary 2000 The taxanes: an update Lancet 355 1176 8
14. JA Ajani DH Ilson K Daugherty R Pazdur PM Lynch DP Kelsen 1994 Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus J Natl Cancer Inst 86 1086 91
15. JA Ajani J Fairweather P Dumas YZ Patt R Pazdur PF Mansfield 1998 A phase II study of Taxol in patients with advanced gastric carcinoma Cancer J Sci Am 4 269 74
16. A Ohtsu N Boku F Tamura K Muro Y Shimada K Saigenji 1998 An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer Am J Clin Oncol 21 416 9
17. A Sulkes J Smyth C Sessa LY Dirix JB Vermoken S Kaye 1994 Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group Br J Cancer 70 380 3
18. ®) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Med Oncol 13 87 93
19. D Mavroudis C Kourousis N Androulakis K Kalbakis S Agelaki S Kakolyris 2000 Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial Am J Clin Oncol 23 341 4
20. T Taguchi Y Sakata R Kanamaru M Kurihara M Suminaga J Ota 1998 Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A) (in Japanese) Jpn J Cancer Chemother 25 1915 24
21. M Mai Y Sakata R Kanamaru M Kurihara M Suminaga J Ota 1999 A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a Cooperative Study Group trial (group B) (in Japanese) Jpn J Cancer Chemother 26 487 96
22. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial Jpn J Clin Oncol 32 248 54
23. AM Murad A Petroianu RC Guimaraes BC Aragao LO Cabral AO Scalabrini-Neto 1999 Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe and effective regimen Am J Clin Oncol 22 580 6
24. E Kettner K Ridwelski U Keilholtz T Gallkowski H Gebauer K Kroning 2001 Docetaxel and cisplatin combination therapy for advanced gastric cancer: results of two phase II studies (abstract) Proc Am Soc Oncol 20 165
25. K Ridwelski T Gebauer J Fahlke H Kroning E Kettner F Meyer 2001 Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer Ann Oncol 12 47 51
26. AD Roth R Maibach G Martinelli N Fazio MS Aapro O Pagani 2000 Docetaxel (Taxotere) - cisplatin (TC): an effective drug combination in gastric carcinoma Ann Oncol 11 301 66
27. JA Ajani M Fodor E Van Cutsem S Tjulandin V Moiseyenco A Cabral 2000 Multinational randomized phase II trial of docetaxel and cisplatin with or without 5-fluorouracil in patients with advanced gastric cancer or GE junction adenocarcinoma (abstract) Proc Am Soc Clin Oncol 19 247
28. S Cascinu F Graziano S Barni R Labianca G Comella R Casaretti 2001 A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian Group for the Study of Digestive Tract Cancer Br J Cancer 84 470 4
29. YH Kim SW Shin BS Kim JH Kim JG Kim YJ Mok 1999 Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric cancer Cancer 85 295 301
30. C Bokemeyer JT Hartmann CS Lampe MR Clemens D Quietzsch L Forkmann 1997 Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer Semin Oncol 24 S19-96 100
31. S Kohnoe M Yoshida I Takahashi Y Emi Y Maehara K Sugimachi 1992 Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells Anticancer Res 12 389 92
32. CTC version 2.0. Cancer Therapy Evolution Program. Common Toxicity Criteria, version 2.0. DCTD, NCI, NIH and DHS, March 1998
33. World Health Organization (WHO). Handbook for reporting results of cancer treatment. Geneva: WHO Offset publication No. 48; 1979
34. JS Andersen HA Burris E Casper MR Green ML Rothemberg MR Modiano 1994 Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer (abstract) Proc Am Soc Clin Oncol 13 461
35. P Laurén 1965 The two histological main types of gastric carcinoma: a diffuse and so-called intestinal type carcinoma Acta Pathol Microbiol Scand 64 31 49
36. S Cullinan C Moertel T Fleming JR Rubin JE Krook LK Everson 1985 A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma JAMA 253 2061 7
37. F Honecker C Kollmannsberger D Quietzsch C Haag M Schroeder C Spott 2002 Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer Anticancer Drugs 13 497 503
38. Roth AD, Maibach R, Falk S, Stupp R, Saletti P, Kaberle D, et al. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol 2004;23: abstract 4020. Updated data presented at the 2004 ASCO annual meeting (see www.ASCO.org for virtual meetings)
39. V Moiseyenko E Van Cutsem S Tjulandin Y Tchao S Sengupta E Zuber 2002 Docetaxel-cisplatin-5-FU (DCF) versus cisplatin-5-FU (CF) as first line therapy for gastric cancer: interim analysis results on efficacy and safety in a multicenter randomized phase III study (abstract) Proc Am Soc Clin Oncol 21 147a
40. Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, et al. Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003;22:249 abstract 999; and associated slide presentation (www.asco.org/ac/1,1003,_12-002511-00_18- 0023-00_19-002584,00.asp)
41. E Van Cutsem 2004 The treatment of advanced gastric cancer: new findings on the activity of the taxanes Oncologist 9 Suppl 2 9 15
42. RC Coombes CE Chilvers D Amadori F Medi G Fountzilas H Rauschecker 1994 Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study Ann Oncol 5 33 6